Investors


Investor Relations


Interim Summary

TurnoverQ4 2020

46 (20)

MSEK

EBITDAQ4 2020

-5 (-4)

MSEK

Christer Ahlberg
President and CEO

CEO Comments

2020 was, to say the least, an exceptional year, as a result of the COVID-19 pandemic, which posed great challenges. As far as Sedana Medical is concerned, I am proud that we succeeded in helping medical care in many places around the world in 2020. In addition, our therapy really had an opportunity to show how much it can offer, both to individual patients and to medical care as a whole.

The fourth quarter was notable for intensive work, firstly with activities ahead of the launch of Sedaconda in Europe during the second half of 2021 and secondly with preparations ahead of our future phase III studies in the United States.

The COVID-19 pandemic has a great impact on our entire business operation, as ICU sedation is precisely the therapy that severely ill COVID-19 patients often need. As our therapy potentially leads to fewer side effects and better oxygen uptake in the lungs, demand for AnaConDa and its accessories was strong during the year. An additional factor contributing to strong demand is that the therapy contributes to increased patient capacity in ICU, which has been important during the pandemic.

Sales showed strong increase in the quarter by as much as 129 percent (137% excluding currency effects), to SEK 46 million, and sales for the full year doubled to SEK 142 million. We interpret this as indicating that the initial sales pressure due to the pandemic has increased again as a result of a second wave with a rise in the number of COVID-19 patients in intensive care units, but also that the ICUs, including new ones, are continuing to use our therapy for patients other than those being treated for COVID-19. We are also seeing an increase in demand in new regions such as Central and South America as a consequence of their severe COVID-19 situation.

The results for some of the secondary endpoints in the phase III study forming the basis for clinical registration Sedaconda (SED-001) were presented at the ESICM congress in December. The secondary endpoints show that Sedaconda (isoflurane) enables faster and controlled recovery, reduced need for opiates and a higher proportion of spontaneous breathing compared with propofol. A high proportion of spontaneous breathing is important as it improves the prospects of lung function being maintained during and other ventilator therapy.

The Sedaconda study was designed as a non-inferiority study, which means that its primary purpose is to show that our therapy is not inferior to propofol in maintaining an adequate sedation level. Based specifically on the study design, the good results for the study’s secondary endpoints were not something we had anticipated. We have seen in previous studies that inhaled sedation has a faster and predictable recovery time, but it is highly positive to have this confirmed in a large, randomised study. Being able to reduce the use of opiates for these patients and make spontaneous breathing possible using the therapy is of great clinical significance. The full results of the study will be presented in a scientific journal in 2021.

The top-line results reported in July 2020 show that Sedaconda, delivered via AnaConDa, is an effective and safe method of sedation for mechanically ventilated intensive care patients comparable to propofol. The results will form the basis for the application for market approval for the drug candidate Sedaconda for inhaled sedation in intensive care units that we submitted in November to the German regulatory authority BfArM and a number of other European regulatory authorities under what is known as a DCP procedure.

The application marks the starting point for the review process for Sedaconda in 15 EU Member States, including Norway. If all goes well, we anticipate authorisation during the second half of 2021. An application for a second group of EU Member States can then be submitted. It normally takes around six months to obtain authorisation for a second group of countries.

When we obtain marketing authorisation for Sedaconda, we will be able to exclusively launch the inhaled sedation therapy in Europe. The therapy consists of our pharmaceutical product Sedaconda , which will then be authorised to only be administrated via our medical device AnaConDa. We chose Sedaconda as the name to highlight the link to Sedana Medical and the pharmaceutical product’s unique use in sedation. At the same time, we communicate that the pharmaceutical product is to be delivered via AnaConDa by retaining CONDA in the name.

The European authorisation will provide very good support in future registration processes in other markets where we are working to make inhaled sedation a standard method within intensive care. After the end of the quarter, we submitted applications to Switzerland and the United Kingdom, which following Brexit works solely with national applications. Our work on the European study has taught us a lot that we benefit from in the design and execution of the American studies, for example.

Now that we are approaching commercialisation in Europe, our work has been focused on launching activities in Europe, while our work in the United States has also intensified, albeit on preparations ahead of the phase III studies. We are working towards being able to submit an IND (Investigational New Drug) application during the summer of 2021 to obtain authorisation to begin the studies. IND authorisation is conditional on the commenced toxicity studies being completed. It is therefore gratifying to be able to note that these studies have progressed at a good pace and according to plan. Depending on how the pandemic develops, we anticipate being able to obtain IND authorisation during the summer in order to be able to include the first patient in each study during the second half of 2021.

A further patent for AnaConDa was granted during the quarter. The technique protected by the patent enables what is known as dead space to be reduced, using inserts and is key to the continued development of inhaled sedation. A decrease in dead space for mechanically ventilated patients is always desirable for intensive care, as it makes lung-protective ventilation possible in comparison with higher dead space. As well as seeing great clinical benefits, we are greatly strengthening our patent protection with this patent. Any competitors or ordinary, passive HME filters will not be able to reduce their dead spacing using inserts without infringing our new patent. The patent has been granted in Europe, and we have also filed a patent application in the United States and other countries.

I would like to take the opportunity to thank all the employees for their great contribution during an intensive and challenging 2020. The fourth quarter has really laid the foundation for a very exciting 2021, with the launch in Europe and the first patients being included in our clinical trials in the United States.

I look forward to coming back to you during the year.

Christer Ahlberg, President and CEO

 Read the report in its entirety here.

Calendar
Dates for upcoming information

Date Event
15 April, 2021 Annual report 2020
6 May, 2021 Q1 interim report 2021
10 May, 2021 Annual General Meeting
12 August, 2021 Q2 interim report 2021
4 November, 2021 Q3 interim report 2021

Annual & Interim Reports

2016
Annual Reports Interim Reports
2016  Sedana Medical AB (publ)
Annual Report 2016 (in Swedish)
N/A N/A

Click on the + sign to expand reports on desired year, then click on a report to open it.
You need a pdf reader to view the files.

Content

Annual General Meeting 2021

Downloadable files:

Annual General Meeting 2020

Downloadable files:

Annual General Meeting 2019

Downloadable files:

Annual General Meeting 2018

Downloadable files:

  Notice of Annual General Meeting 2018
  Nomination Committee’s proposal
  Power of Attorney form
  Minutes of the Annual General Meeting


Corporate Governance

Corporate governance includes information about our Board of Directors, the management team, guidelines for remuneration to the senior management, our auditors, general meetings and our articles of association.

Board of Directors

The registered office of the company is situated in the municipality of Danderyd. The Board of Directors shall consist of not less than three (3) and not more than six (6) members.

Thomas Eklund Chairman
of the Board
  • Born: 1967
  • Nationality: Swedish
  • Position: Board member and Chairman of Sedana Medical since 2014.
  • Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.
  • Other current engagements: Board member in Biotage AB, Bio-Works Technologies AB, Bio-Works Sweden AB, Boule Diagnostics AB, Excillum Aktiebolag, Immedica Pharma Holding AB, Mabtech Group Holding AB, Mabtech Holding AB, Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 416,616 shares via Tedsalus AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Sten GibeckMember
of the Board
  • Born: 1943
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2005. Formerly Chairman of the Board.
  • Education and professional experience: Sten holds a higher business economics qualification from the National Swedish Union of Clerical Employees. Sten is a former owner and CEO of Louis Gibeck AB during its journey from being a small distribution company to achieving a leading position in its field in e.g. Germany, France, Japan and the USA.
  • Other current engagements:
  • Shareholding in Sedana Medical: 1,219,944 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Bengt Julander Member
of the Board
  • Born: 1953
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2011.
  • Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Chairman in Linc AB, with investments in the pharmaceutical and medtech industry.
  • Other current engagements: Chairman in Linc AB and Knil AB. Board member in Animal Probiotics Sweden AB, Cronhamn Invest AB, Livland Skog AB, Medivir Aktiebolag, nWise AB, Part Production Sweden AB, Reison Medical AB, Stille AB and Swevet Holding AB. Board member and deputy board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,899,701 shares via Linc AB.
    Independent in relation to the Company and its management but not in relation to major shareholders.
Ola Magnusson
Member
of the Board
  • Born: 1948
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2005. Formerly CEO of Sedana Medical (2005 – 2011).
  • Education and professional experience: Ola hold an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry mainly within marketing, sales and different management positions including 4 years in the US for Pharmacia in the 80ies and 90ies. Ola also has more than 20 years experience in the medical device industry as CEO for Louis Gibeck AB where he was responsible for the listing on the OTC exchange in Stockholm and as Managing Director EMEA, Hudson RCI AB after its acquisition of Louis Gibeck AB. Ola was the founder of Sedana Medical 2005 and acted as CEO up to 2011.
  • Other current engagements: Chairman in Eataway AB. Board member in TransCutan AB and board member in smaller family companies.
  • Shareholding in Sedana Medical: 1,157,432 shares privately and via Magiola Consulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Eva Walde Member
of the Board
  • Born: 1963
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2018.
  • Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.
  • Other current engagements: Vice President Marketing Director at Olink Proteomics AB, board member at Senzime AB, CEO and Chairman of the board in the own company Movits Consulting AB and deputy board member in Finnson & Partners AB.
  • Shareholding in Sedana Medical: 3,200 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Christoffer Rosenblad Member
of the Board
  • Born: 1975
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2020.
  • Education and professional experience: Christoffer has a Master of Science degree from Chalmers University of Technology and a degree in economics from the School of Business and Economics at the University of Gothenburg. During 2012-2020 he was CFO for XVIVO Perfusion AB. During the years 2015–2017, he led XVIVO’s North American operations and resided in the United States. From 2001 to 2012, he has had leading positions in finance and strategic management at Novartis and LG Electronics.
  • Other current engagements: COO (since 2020) and Vice President (since 2017) at XVIVO Perfusion AB.
  • Shareholding in Sedana Medical: no shares.
    Independent in relation to the Company and its management and in relation to major shareholders.

Management team

Christer Ahlberg
President and CEO
  • Born: 1971
  • Nationality: Swedish
  • Position: President and Chief Executive Officer of Sedana Medical since February 2017, employed since 2017.
  • Education and professional experience: Christer holds a BSc in business administration and economics from Örebro University.Former experience in the pharmaceutical industry includes CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth.
  • Other current engagements: Board member in FrostPharma AB, Prooxpharma AB and Glycorex Transplantation AB. CEO and deputy board member in Waxholm by the sea aktiebolag.
  • Shareholding in Sedana Medical: 259,000 shares.
Susanne Andersson
CFO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Financial Officer since January 2021.
  • Education and professional experience: Bachelor of Business Administration from College of Charleston, S.C. USA. CFO at Pricer, CFO & Head of Communications at ChromoGenics, VP Head of Investor Relations at PostNord, CFO at Nordic Mines and 15+ years of international experience of various finance and management roles within Ericsson and the telecom industry.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Sylvia Buddenbaum Eriksson
HR director
  • Born: 1968
  • Nationality: Swedish
  • Position: HR director, Consultant since August 2020.
  • Education and professional experience: B.Sc. Business and Economics, Stockholm University. Consultant own business since February 2019. Previously i.a. HR director GroupM, HR director Lidl Sweden, HR & Communication Apoteksgruppen AB/Apoteket omstrukturering AB, HR director Unilever Nordic and different roles within finance.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares, Related parties 118 shares.
Robert vom Dorp
Vice President Business Development
  • Born: 1970
  • Nationality: German
  • Position: Vice President Business Development since April 2020, employed
    since 2005.
  • Education and professional experience: Robert holds an MBA in economics from the University of Applied Sciences at Hochschule Koblenz. Has also studied industrial organisation. Experience in sales in the medtech industry since 2001 as account manager within anaesthesia, ventilation and intensive care at Hudson RCI and Teleflex Medical. Sales manager at Sedana Medical with responsibilities for marketing, sales, strategy and operations in Germany, Austria and Switzerland.
  • Other current engagements:
  • Shareholding in Sedana Medical: 100,000 shares.
Peter Fröberg
Chief Technology Officer
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Technology Officer, Consultant since November 2020.
  • Education and professional experience: MSc from the Royal Institute of Technology in Stockholm. More than 20 years’ experience of product and business development, as product manager at Elekta Instrument AB and as a consultant within Life Science.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Stefan Krisch
Supply Chain and Manufacturing Director
  • Born: 1974
  • Nationality: Swedish
  • Position: Supply Chain and Manufacturing Director since March 2021.
  • Education and professional experience: : Stefan holds a Master of Science degree in Mechanical Engineering from KTH Stockholm, Sweden, and TUD Darmstadt, Germany. In addition he studied business administration and management at Stockholm Business School, Stockholm University. Stefan has some 20 years of experience in leading positions in various industries. Mainly within manufacturing, logistics, and business development. Previously CEO of Svensk Dos AB, CEO of Dipylon Medical AB and Production Manager at AB Gustavsberg. Founder of Eker Bicycles AB and Eker Production Ltd., Uganda.
  • Other current engagements: Chairman of the Board Eker Bicycles AB and Eker Production Ltd., Uganda. Owner K-Consulting (sole proprietor).
  • Shareholding in Sedana Medical: 1400 shares, 6300 warrants.
Jens Lindberg
Vice President Commercial Operations
  • Born: 1971
  • Nationality: Swedish
  • Position: Vice President Commercial Operations since April 2020, employed since 2020.
  • Education and professional experience: B.S. Business Administration & 25 years of experience from local & global commercial roles in AstraZeneca.
  • Other current engagements:
  • Shareholding in Sedana Medical: 0 shares. 3,000 warrants in program 2020/2023
    representing 3,000 shares.
Peter Sackey
CMO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Medical Officer of Sedana Medical since January 2018, employed since 2018.
  • Education and professional experience: Peter received his doctor´s degree from Karolinska Institutet in 1997. He has worked for twenty years at the Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital and is Board-certified in Anesthesiology (DESA) and Intensive Care (EDIC). He completed his PhD thesis entitled “Isoflurane sedation in Intensive Care Unit patients” at Karolinska Institutet in 2006. He is an Associate professor at Karolinska Institutet, has supervised several PhD students and has active ICU-related research.
  • Previous positions: Senior Consultant, Head of Neurocritical Care, Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital in Stockholm.
  • Other current engagements: Associate professor, Department of Physiology and Pharmacology, Karolinska Institutet.
  • Shareholding in Sedana Medical: 63,142 shares and 26,293 warrants in program 2019/2022 representing 26,293 shares.
Jessica Westfal
Vice President Regulatory Affairs and QA
  • Born: 1974
  • Nationality: Swedish
  • Position: Vice President Regulatory Affairs and QA since May 2020, employed since 2020.
  • Education and professional experience: Jessica holds a MSc in Analytical Chemistry at
    Umeå University. She is a former employee at Unimedic AB (between 2006-2020) as Head of Quality and Product Development, and before that at AstraZeneca (between 1998-2006).
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares. 1,000 warrants in program 2020/2023
    representing 1,000 shares.

Guidelines for remuneration to senior management

The main principle is that remuneration and other employment conditions for members of senior manage¬ment shall be based on market terms and be competitive in order to ensure that the group can attract and retain competent senior managers at a reasonable cost for the company.

The total remuneration for senior management shall consist of fixed salary, variable remuneration, pension and other benefits.

The Board fee is decided by the Annual General Meeting. In so far as board members elected by the Annual General Meeting are performing work that stretches beyond the tasks of the Board of Directors, it shall be possible to pay them for such work. Such remuneration shall be market-based and shall be approved by the Board of Directors.

The remuneration to the Board of Sedana Medical is determined at the Annual General Meeting following proposals from the Nomination Committee.

Audit Committee

During 2020 an audit committee was established. On behalf of the Board, the Audit Committee monitors and reviews the following:

  • The scope and correctness of the financial statements
  • Compliance with legal and regulatory requirements
  • Internal control over financial reporting
  • Risk management
  • The Annual Report and interim reports
  • Audits and audit fees

Members of the Audit Committee
The Audit Committee consists of three Board members as appointed by the Board. The current members are:
Christoffer Rosenblad (Chairman of the Committee)
Thomas Eklund
Bengt Julander

Auditor

Öhrlings PricewaterhouseCoopers AB was elected as auditors at the Annual General Meeting in May 2020 for the period leading up to the Annual General Meeting 2020. The principal responsible is authorized public accountant Leonard Daun.

Fees for auditing in Sedana Medical are determined at the AGM following proposals from the Nomination Committee.

General Meeting

The General Meeting of shareholders is the highest decision-making entity in Sedana Medical AB. At the General Meeting, all shareholders are invited to exercise their rights according to their respective shareholdings.

Shareholders wishing to participate in General Meetings must be listed as a shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

ARTICLES OF ASSOCIATION OF SEDANA MEDICAL AB (PUBL)

Reg. no. 556670-2519

Adopted at the annual general meeting held on 19 May 2020

§ 1 Name of the company
The name of the company is Sedana Medical AB (publ).

§ 2 Registered office of the board of directors
The registered office of the company shall be situated in the municipality of Danderyd.

§ 3 Object of the company’s activities
The object of the company’s activities is to develop, manufacture and market pharmaceuticals and medical- technical products, and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 800,000 and not more than SEK 3,200,000.

§ 5 Number of shares
The number of shares shall be not less than 8,000,000 and not more than 32,000,000.

§ 6 Board of Directors
The board of directors shall consist of not less than three (3) and not more than six (6) members. The members are to be elected annually at the annual general meeting until the end of the next annual general meeting.

§ 7 Auditors
The company shall have a minimum of one (1) and a maximum of two (2) auditors, with a maximum of two (2) deputy auditors. A registered accounting firm may also be appointed as auditor.

§ 8 Place of General Meetings
Any general meeting in the Company shall be held in Danderyd or Stockholm.

§ 9 Notice of General Meeting
Notices of general meetings shall be made by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. At the same time as notice is given it shall be announced in Dagens industri that a notice has been made.
Shareholders wishing to participate at a general meeting shall notify the company no later than the date specified in the notice of the general meeting. Such date may not be a Sunday, other public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday before the general meeting. A shareholder may be accompanied by advisors at a general meeting only if he or she notifies the company of the number of advisors in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

§ 10 Annual General Meeting
The following matters shall be addressed at the annual general meeting:

1. Election of chairman of the meeting

2. Preparation and approval of the voting register

3. Election of one or two persons to attest the minutes

4. Determination of whether the meeting has been duly convened

5. Approval of the agenda

6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated financial statements and the auditor’s report on the group

7. Resolutions regarding:

(a) adoption of the balance sheet and income statement and, where applicable, the consolidated balance sheet and the consolidated income statement

(b) allocation of the company’s profit or loss according to the adopted balance sheet

(c) discharge from liability for board members and the managing director

8. Determination of fees to be paid to the board of directors and the auditors

9. Determination of the number of board members and, where applicable, deputy members, and the number of auditors and, where applicable, deputy auditors

10. Election of the board of directors and auditors

11. Any other business incumbent on the meeting according to the Swedish Companies Act or the articles of association

§ 11 Financial year
The company’s financial year shall be 1 January – 31 December.

§ 12 CSD clause
The shares of the company shall be registered in a CSD register in accordance with the Central Securities Depositaries and Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

 Click here to download the Articles of Association.

Ownership

Below is Sedana Medical’s ownership structure.

NameNum. of sharesCapitalVotesVerified       
Handelsbanken Funds 2,198,763 9.54% 9.54% 2021-03-31
Swedbank Robur Funds 2,110,895 9.16% 9.16% 2021-03-31
Linc AB (Bengt Julander) 1,899,701 8.24% 8.24% 2021-03-31
Anders Walldov 1,740,000 7.55% 7.55% 2021-03-31
Sten Gibeck 1,219,944 5.29% 5.29% 2021-03-31
Ola Magnusson 1,153,432 5.00% 5.00% 2020-12-14
Öhman Funds 772,659 3.35% 3.35% 2021-03-31
Berenberg Funds 609,440 2.64% 2.64% 2020-10-31
Avanza Pension 529,629 2.30% 2.30% 2021-03-31
Third Swedish National Pension Fund 475,000 2.06% 2.06% 2021-03-31
Total 1012,709,46355.15%55.15%
Others10,337,27744.85%44.85%
Total number of owners 6,536 2021-03-31
Total number of shares 23,046,740 2021-03-31

Source: Modular Finance

Warrant programmes

Sedana Medical has outstanding warrant programmes with a total maximum dilution of 136 818 shares.
Warrant program 2019/2022, total maximum dilution of 89 085 shares,
exercisable 1 July to 30 November 2022 at a strike price of 142.23 SEK per share.
Warrant program 2020/2023, total maximum dilution of 10 620 shares,
exercisable 1 July to 30 November 2023 at a subscription price of SEK 334.60 per share.
Warrant program 2020/2024, total maximum dilution of 37 113 shares,
exercisable 1 February to 31 May 2024 at a subscription price of SEK 495.52 per share.

Presentations

Date Description Material
Feb 25, 2021 Sedana Medical – webcast Q4 report.  More info
Nov 26, 2020 Sedana attending Redeye Life Science Day 2020.  Play Video
Nov 17-19, 2020 Sedana attending 11th Annual Jefferies Global Healthcare Conference.  More info
Nov 5, 2020 – 14:00 Sedana Medical – webcast Q3 report.  More info
Sept 9, 2020 Sedana attending Carnegie Virtual Nordic Small Mid Cap Seminar.  View Program
Sept 2-3, 2020 Sedana attending Pareto Securities’ 11th Annual Healthcare Conference.  More info
Sept 1, 2020 Sedana attending Danske Bank Small & Mid Cap Seminar.  Play Video
July 10, 2020 Presentation of the positive top line result in the pivotal IsoConDa study.  Play Live Stream
May 19, 2020 CEO presentation in connection with AGM 2020-05-19.  Play Video
May 7, 2020 Presentation of the interim report for the first quarter 2020.  Play Video
April 8, 2020 Sedana Medical’s CEO on prioritizing in the Corona crisis.  Play Video
November 27, 2019 VATOR SECURITIES UNICORN SUMMIT 2019.  Play Video
September, 2019 Sedana Medical – Management Presentation September 2019.  View Presentation
June 10, 2019 Redeye Growth Day 2019.  Play Video
May 8, 2019 Presentation of the interim report for the first quarter 2019.  Play Video
March 14, 2019 Stockholm Corporate Finance Life Science Seminar.  Play Video
March 8, 2019 IsoConDa phase III pivotal study, interim analysis report, 8 March 10:30.  Play Video
September 6, 2018 Pareto Securities’ 9th Health Care seminar in Stockholm.  Play Video
April 27, 2018 Event at ProHearings (English).  Play Video
March 7, 2018 Sitdown at Erik Penser 2018 (Swedish).  Play Video
March 6, 2018 Stockholm Corporate Finance Life Science Seminar (Swedish).  Play Video
November 24, 2017 Redeye seminar (Swedish).  Play Video
June 29, 2017 Trading Direkt Interview with CEO Christer Ahlberg (Swedish).  Play Video

Shares

Stock Graph

Stock Table

Stock
Sedana Medical
Stock
SEDANA
Latest Price
325.0 SEK
Return today
+0.0%
MCAP
7 490 MSEK
Return this year
-5.2%
Total return this year
-5.2%
Year Low
317.5 SEK
Year High
400.0 SEK
ATH
400.0 SEK
Share
ISIN-code
Share
Shortname
Current
Share Price
SE0009947534 SEDANA  Click here!
The LEI code is: 549300FQ3NJRI56LCX32
Certified Adviser: Erik Penser Bank – Tel: +46 (0)8-463 80 00 – Apelbergsgatan 27, Box 7405, 103 91 Stockholm, Sweden
Analyst(s) covering Sedana Medical: Peter Östling, Pareto Securities

IPO

 Sedana Medical Investor Relation

 

Address:
Sedana Medical AB (publ)
Vendevägen 89
SE-182 32 Danderyd
Sweden
Phone: +46 (0)8-124 05 200
Investor relation: ir@sedanamedical.com